Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

Authors: Aroda, Vanita R., Frias, Juan Pablo, Ji, Linong, Niemoeller, Elisabeth, Nguyên‐Pascal, My‐Liên, Denkel, Karl, Espinasse, Melanie, Guo, Hailing, Baek, SeungJae, Choi, JaeDuk, Lingvay, Ildiko

Source: Diabetes, obesity & metabolism. 25(8):2084-2095

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100186344711.0x000001&indx=1&recIds=ETOCvdc_100186344711.0x000001

Obesity among Latinx people in the United States: A review

Authors: Alemán, José Orlando, Almandoz, Jaime P., Frias, Juan Pablo, Galindo, Rodolfo J.

Source: Obesity. 31(2):329-337

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173003876.0x000001&indx=1&recIds=ETOCvdc_100173003876.0x000001

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

Authors: Loomba, Rohit, Lawitz, Eric J, Frias, Juan Pablo, Ortiz-Lasanta, Grisell, Johansson, Lars, Franey, Bridgette Boggess, Morrow, Linda, Rosenstock, Moti, Hartsfield, Cynthia L, Chen, Chao-Yin, Tseng, Leo, Charlton, R Will, Mansbach, Hank, Margalit, Maya ^*

Source: In The Lancet Gastroenterology & Hepatology February 2023 8(2):120-132

Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2

Authors: Danne, Thomas, Edelman, Steven, Frias, Juan Pablo, Ampudia‐Blasco, Francisco Javier, Banks, Philip, Jiang, Wenjun, Davies, Michael J., Sawhney, Sangeeta

Source: Diabetes, obesity & metabolism. 23(3):854-860

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121426319.0x000001&indx=1&recIds=ETOCvdc_100121426319.0x000001

The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device

Authors: Frias, Juan Pablo, Koren, Michael J., Loizeau, Virginie, Merino-Trigo, Ana, Louie, Michael J., Raudenbush, Mary Alice, Batsu, Isabela

Source: In Clinical Therapeutics January 2020 42(1):94-107

Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal

Authors: Vargas-Uricoechea, Hernando, Frias, Juan Pablo

Source: In Diabetes & Metabolic Syndrome: Clinical Research & Reviews May-June 2019 13(3):1975-1989

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Authors: Frias, Juan Pablo, Nauck, Michael A., Van, Joanna, Benson, Charles, Bray, Ross, Cui, Xuewei, Milicevic, Zvonko, Urva, Shweta, Haupt, Axel, Robins, Deborah A.

Source: Diabetes, obesity & metabolism. 22(6):938-946

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100114723127.0x000001&indx=1&recIds=ETOCvdc_100114723127.0x000001

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Authors: Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio

Source: Diabetes, obesity & metabolism. 22(9):1567-1576

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100107989796.0x000001&indx=1&recIds=ETOCvdc_100107989796.0x000001

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes

Authors: Handelsman, Yehuda, Chovanes, Christina, Dex, Terry, Giorgino, Francesco, Skolnik, Neil, Souhami, Elisabeth, Stager, William, Niemoeller, Elisabeth, Frias, Juan Pablo

Source: In Journal of Diabetes and Its Complications March 2019 33(3):236-242

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Authors: Frias, Juan Pablo, Nauck, Michael A, Van, Joanna, Kutner, Mark E, Cui, Xuewei, Benson, Charles, Urva, Shweta, Gimeno, Ruth E, Milicevic, Zvonko, Robins, Deborah, Haupt, Axel

Source: In The Lancet 17-23 November 2018 392(10160):2180-2193

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

Authors: Blonde, Lawrence, Bailey, Timothy S., Chao, Jason, Dex, Terry A., Frias, Juan Pablo, Meneghini, Luigi F., Roberts, Michelle, Aroda, Vanita R.

Source: Advances in therapy. 36(9):2310-2326

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100124728519.0x000001&indx=1&recIds=ETOCvdc_100124728519.0x000001

Prioritising injectable therapies in the management of type 2 diabetes

Authors: Frias, Juan Pablo

Source: Lancet.Diabetes & endocrinology. 7(7):505-508

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183239160.0x000001&indx=1&recIds=ETOCvdc_100183239160.0x000001

Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes

Authors: Frias, Juan Pablo

Source: Expert review of endocrinology & metabolism. 14(2):75-83

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100103366241.0x000001&indx=1&recIds=ETOCvdc_100103366241.0x000001

BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

Authors: Frias, Juan Pablo, Ortiz-Lasanta, Grisell, Hartsfield, Cynthia L., Tseng, Leo, Charlton, R. William, Mansbach, Hank, Margalit, Maya, Loomba, Rohit

Source: Metabolism, clinical and experimental. 128(S)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100157973238.0x000001&indx=1&recIds=ETOCvdc_100157973238.0x000001

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Authors: Frias, Juan Pablo, Bastyr, Edward J., III, Vignati, Louis, Tschöp, Matthias H., Schmitt, Christophe, Owen, Klara, Christensen, Rune Haubo, DiMarchi, Richard D.

Source: In Cell Metabolism 1 August 2017 26(2):343-352

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes

Authors: Frias, Juan Pablo

Source: Journal of family practice. 67(6):S25-S34

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN616682384&indx=1&recIds=ETOCRN616682384

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

Authors: Schnell, Oliver, Barnard-Kelly, Katharine, Battelino, Tadej, Ceriello, Antonio, Larsson, Helena Elding, Fernández-Fernández, Beatriz, Forst, Thomas, Frias, Juan-Pablo, Gavin III, James R., Giorgino, Francesco, Groop, Per-Henrik, Heerspink, Hiddo J. L., Herzig, Stephan, Hummel, Michael, Huntley, George, Ibrahim, Mahmoud, Itzhak, Baruch, Jacob, Stephan, Ji, Linong, Kosiborod, Mikhail

Source: Cardiovascular Diabetology; 3/19/2024, Vol. 23 Issue 1, p1-17, 17p

Subject Terms: HEART failure, CONTINUOUS glucose monitoring, THERAPEUTICS, MAJOR adverse cardiovascular events, TYPE 1 diabetes, CARDIOVASCULAR diseases

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.

Authors: Frias, Juan Pablo, Choi, JaeDuk, Rosenstock, Julio, Popescu, Luiza, Niemoeller, Elisabeth, Muehlen-Bartmer, Isabel, Baek, Seungjae sjbaek.md@gmail.com

Source: Diabetes Care. jul2022, Vol. 45 Issue 7, p1592-1600. 9p.

Subject Terms: *RESEARCH, *BODY weight, *COMBINATION drug therapy, *GLUCAGON-like peptide 1, *RESEARCH methodology, *HYPOGLYCEMIC agents, *BLOOD sugar, *EVALUATION research, *TYPE 2 diabetes, *TREATMENT effectiveness, *COMPARATIVE studies, *RANDOMIZED controlled trials, *BLIND experiment, *PROLINE, *METFORMIN

Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m².

Authors: Danne, Thomas, Edelman, Steven, Frias, Juan Pablo, Ampudia‐Blasco, Francisco Javier, Banks, Philip, Jiang, Wenjun, Davies, Michael J., Sawhney, Sangeeta

Source: Diabetes, Obesity & Metabolism; Mar2021, Vol. 23 Issue 3, p854-860, 7p

Subject Terms: SODIUM-glucose cotransporters, TYPE 1 diabetes, BODY mass index, DRUG efficacy, SODIUM-glucose cotransporter 2 inhibitors, INSULIN

Geographic Terms: EUROPE

Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.

Authors: Frias, Juan Pablo¹ jfrias@clinical-studies.com, Lorenz, Martin², Roberts, Michelle³, Dex, Terry³, Schmider, Wolfgang⁴, Hurst, William³, Skolnik, Neil⁴, Pablo Frias, Juan⁵ (AUTHOR)

Source: Current Medical Research & Opinion. 2019, Vol. 35 Issue 4, p689-695. 7p.

Subject Terms: *TYPE 2 diabetes, *GLYCOSYLATED hemoglobin, *GASTRIC emptying, *MATHEMATICAL combinations